Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Completed · Phase 2

Conditions studied: Ocular Hypertension, Primary Open-Angle Glaucoma

In brief

This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days. Part 2 will evaluate the safety and IOP effects of a formulation (to be selected from part 1) of AGN-210961 in both eyes compared to bimatoprost ophthalmic solution 0.03% for 4 weeks.

Key facts

Study ID

NCT01110499

Run by

Allergan

People needed

163

Starts

2010-06-01

Expected to finish

2011-06-01

Last updated by the study team

2014-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ocular hypertension or primary open-angle glaucoma in each eye

You may not qualify if…

• Any active ocular disease
• Anticipated wearing of contact lenses during study
• Anticipated use of artificial tears during study
• Contraindication to pupil dilatation

Where it is running

• Study site — Newport Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.